FDA Confirms RX7 Articulaciones Contains Undeclared Diclofenac and Dexamethasone

Laboratory analysis by the FDA has confirmed that RX7 Articulaciones, a product marketed for joint and muscle pain through online platforms including eBay and select retail outlets, contains undeclared diclofenac and dexamethasone, a finding that sharpens scrutiny on the broader supplement supply chain and the labeling controls legitimate manufacturers maintain under 21 CFR Part 111.

Diclofenac, an NSAID, carries well-documented cardiovascular and gastrointestinal risks, including increased probability of heart attack, stroke, gastrointestinal bleeding, and potentially life-threatening perforation of the stomach or intestinal lining. Its interaction profile with other NSAID-containing products compounds those risks materially. Dexamethasone, a corticosteroid, introduces a separate risk cluster: immunosuppression, hyperglycemia, myopathy, and psychiatric effects. Consumers already using corticosteroids for legitimate indications face compounded exposure without any clinical oversight.

The FDA has advised consumers to discontinue use immediately under healthcare professional supervision, specifically flagging the need for a structured corticosteroid withdrawal assessment. Adverse events should be reported through the MedWatch voluntary reporting program, either via the online submission portal or by fax at 1-800-FDA-0178.

For QA directors and regulatory affairs leads, the enforcement context is relevant: the FDA has explicitly acknowledged it cannot test and identify all dietary supplement products carrying potentially harmful hidden ingredients. That constraint places additional weight on supply-chain due diligence for manufacturers and distributors whose products share retail or e-commerce shelf space with fraudulent entries. Misbranding and adulteration enforcement actions in this category have intensified, and the reputational proximity risk for compliant manufacturers is not negligible.

RX7 Articulaciones is positioned within a documented pattern of pain-relief and joint-support products promoted as "all natural" while containing undisclosed pharmaceutical actives. Plant heads sourcing or co-manufacturing in the supplement space should treat this notification as a prompt to audit incoming raw material testing protocols and finished-product label verification procedures against current GMP expectations.

The MedWatch reporting window remains open, and the volume of adverse event submissions linked to this product will likely inform the scope of any subsequent enforcement action.

Source: U.S. Food and Drug Administration, Medication Health Fraud Notifications, via FDA.gov, October 28, 2026.